Authors
Sara Linciano, Emilia Vigolo, Antonio Rosato, Yoichi Kumada, Alessandro Angelini
First author
Sara Linciano
Corresponding author
Alessandro Angeilni
Publication Style
Journal name Current Opinion in Biotechnology
Year
Volume, issue, pages
90, 103218
Abstract
Small immunomodulatory payloads (IMMs) such as peptide vaccines and cytokines have the capability to activate and boost the immune response against cancer. However, their clinical use has often been hindered by their poor stability and short circulating half-lives. To enhance the pharmacokinetic properties of small IMMs and promote their trafficking and accumulation in lymphatic and tumor tissues, a large variety of strategies have been developed. One of the most successful relies on the use of serum albumin (SA), the most abundant protein in the circulatory and lymphatic system. Here, we report a comparative analysis of the different covalent and noncovalent SA-based strategies applied so far to improve the efficacy of small IMMs in cancer therapy.